Retatrutide 15mg
Triple agonist (GLP-1 / GIP / Glucagon) — investigational metabolic peptide.
Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP and glucagon receptors. In research it has demonstrated some of the largest weight-reduction effects reported for any incretin-class molecule, alongside improvements in glycemic control and hepatic fat.
Benefits
- Pronounced reductions in body weight in trial subjects
- Improved insulin sensitivity and fasting glucose
- Reduced hepatic steatosis markers
- Appetite suppression and slower gastric emptying
Considerations
- GI side effects: nausea, vomiting, constipation, diarrhea
- Possible elevated heart rate
- Rapid loss of lean mass if calories/protein too low
- Long half-life — side effects can linger
Protocol
Subcutaneous injection once weekly. Titrate slowly over 4–8 weeks to limit GI side effects. Cycle 12–24 weeks then assess.
Dosage
Typical research titration: 2 mg/week → 4 mg → 8 mg → 12 mg. Maximum doses studied up to 12 mg weekly.
Reconstitution
10 mg vial: add 2 mL bacteriostatic water (5 mg/mL → 0.4 mL = 2 mg). 15 mg vial: add 1.5 mL BAC water (10 mg/mL).
Always use bacteriostatic water (BAC), sterile technique and store reconstituted vials refrigerated unless otherwise noted.
